( ancer targets. Thecompany has value ge...)Avalon Pharmaceuticals to Present at the American Association for,Cancer Research 2007 Annual Meeting,Health

This announcement contains, in addition to historical information, certain forward-looking statements that involve risks and uncertainties, in particular, related to progress in our drug discovery programs and our collaborations, and clinical progress in the development of AVN944. Such statements reflect the current views of Avalon management and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, risks and uncertainties including the risk that the discovery programs and collaborations may not be successful and that AVN944 will not progress successfully in its clinical trials, and other risks described in our SEC filings. There can be no assurance that our development efforts will succeed, that AVN944 will receive required regulatory clearance or, even if such regulatory clearance is received, that any subsequent products will ultimately achieve commercial success. The information in this Release should be read in conjunction with the Risk Factors set forth in our 2005 Annual Report on Form 10-K and updates contained in subsequent filings we make with the SEC.

    Contacts:

    Avalon Pharmaceuticals, Inc.              Noonan Russo

    Gary Lessing                              Greg Geissman (Media)

    Executive Vice President & CFO            Tel: (619) 814-3510

    Tel: (301) 556-9900

    Fax: (301) 556-9910                       The Trout Group LLC

    Email:                   Chad Rubin (Investors)

                                              Tel: (646) 378-2947

CONTACT: Gary Lessing, Executive Vice President & CFO of AvalonPharmaceuticals, Inc., +1-301-556-9900, ; or
'"/>